Employees: 1,439
Size Chongqing Pharscin Pharmaceutical (002907.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $752M, the 2722nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.15 on 18 Nov 2026.
Performance Over six months the shares fell 6.8%, against -20.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue grew 8.5% over the last twelve months (peer median +2.4%); the operating margin is 9.7% (peer median 8.8%).
Valuation It trades at 5.3× enterprise value to sales against a peer median of 2.5× (5th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.8 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥839M | CN¥814M | CN¥763M | CN¥681M | CN¥773M |
| Revenue growth | — | +7% | +12% | -12% | — |
| Gross profit | CN¥509M | CN¥426M | CN¥402M | CN¥344M | CN¥440M |
| EBITDA | n/a | CN¥141M | CN¥148M | CN¥110M | CN¥170M |
| Net income | CN¥93.8M | CN¥65.1M | CN¥76.7M | CN¥32.7M | CN¥98.4M |
| Free cash flow | CN¥89.7M | CN¥53.5M | CN¥149M | CN¥127M | -CN¥44.3M |
| Capital expenditure | CN¥35.7M | CN¥14.6M | CN¥16.2M | CN¥92.8M | CN¥60.6M |
| Total debt | CN¥2.86M | CN¥41.8M | CN¥127,562 | CN¥281,958 | CN¥169,881 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002907.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.4% | -5.2% | lowest of 19 |
| 6-month return | -6.8% | -20.1% | 6th highest of 19 |
| Distance from 52-week high | -34.2% | -34.6% | 10th highest of 19 |
| Revenue growth (TTM) | +8.5% | +2.4% | 5th highest of 19 |
| Operating margin | 9.7% | 8.8% | 9th highest of 19 |
| EV / Sales | 5.3× | 2.5× | 5th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 9.4% | -2.0% | 4th most demanding of 12 |
| Growth delivered (Del g) | -1.4% | +1.9% | lowest of 12 |
| Hurdle (Req g minus delivered) | +10.7 pp | -3.1 pp | 4th most demanding of 12 |
| ROIC minus cost of capital | +4.8 pp | -0.3 pp | 3rd highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 1.8× | -2.0% | +26.1% |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 1.1× | -11.8% | +1.9% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 3.8× | 5.9% | +11.3% |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | 16.1× | 42.7% | -0.9% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 3.9× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 2.6× | -4.8% | +6.4% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | 0.3× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |